NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Nanobiotix S.A. - ADSs (NBTX)
Company Research
Source: GlobeNewswire
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung studyMultiple clinical readouts expected in 2024 including immunotherapy combination data from Study 1100, and data from MD Anderson program€75.3 million in cash and cash equivalents as of December 31, 2023 with cash runway into Q3 2025 including the $20 million first development milestone due from Janssen2023 Universal Registration Document filed with the French financial market authority and the 2023 Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission Conference call and webcast scheduled for April 25, 2024 at 8:00 A.M. EDT / 2:00 P.M. CEST PARIS and CAMBRI
Show less
Read more
Impact Snapshot
Event Time:
NBTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBTX alerts
High impacting Nanobiotix S.A. - ADSs news events
Weekly update
A roundup of the hottest topics
NBTX
News
- NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 [Yahoo! Finance]Yahoo! Finance
- NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024GlobeNewswire
- NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung CancerGlobeNewswire
- Nanobiotix S.A. (NASDAQ: NBTX) had its "buy" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Nanobiotix reports FY results [Seeking Alpha]Seeking Alpha
NBTX
Analyst Actions
- 4/30/24 - HC Wainwright
NBTX
Sec Filings
- 5/15/24 - Form 6-K
- 5/14/24 - Form 6-K
- 4/24/24 - Form 6-K
- NBTX's page on the SEC website